Filter by: patients
Home > Community Treatment Reports and Side Effects > Parkinson's Phase 3 Study Creatine Treatment Report
What is Parkinson's Phase 3 Study Creatine?

NCT00449865 is a multicenter, double-blind, parallel group, placebo controlled study of creatine in subjects with treated Parkinson's Disease (PD) Long Term Study (LS-1). Other study IDs include: U01NS43128 NET-PD, CRC, NET-PD LS-1.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Participate in clinical trial 2 0
maintain muscle tone and movement 1 0

See all 2 patients currently using Parkinson's Phase 3 Study Creatine

Mouse over the table for more information

Reported Schedules

  1 mg daily 5 g daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Duration See details about how long patients take this treatment ▼

Currently Using Parkinson's Phase 3 Study Creatine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Report created on May 23, 2012.